LRP5; low density lipoprotein receptor-related protein 5; HGNC: 6697; BMND1; HBM; LR3; LRP7; OPPG; OPS; VBCH2; low density lipoprotein receptor-related protein 7; osteoporosis pseudoglioma syndrome; EVR1; EVR4; OPTA1; exudative vitreoretinopathy 1; LRP5 antibody; low density lipoprotein receptor-related protein 5 antibody; HGNC: 6697 antibody; BMND1 antibody; HBM antibody; LR3 antibody; LRP7 antibody; OPPG antibody; OPS antibody; VBCH2 antibody; low density lipoprotein receptor-related protein 7 antibody; osteoporosis pseudoglioma syndrome antibody; EVR1 antibody; EVR4 antibody; exudative vitreoretinopathy 1 antibody

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Goat

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.

Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

100ug specific antibody in 200ul (lot specific)

Aliquot and store at -20 degree C. Minimize freezing and thawing.

Manufactured in an ISO 9001:2008 Certified Laboratory.

Small volumes of anti-LRP5 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Peptide ELISA (EIA), Immunohistochemistry (IHC)

Peptide ELISA: Antibody detection limit dilution 1: 128000.
Immunohistochemistry: In paraffin embedded Human Kidney shows primarily nuclear envelope staining in PCT-. Recommended concentration, 3-6ug/ml.
Western Blot: Not suitable for WB.

(4ug/ml) staining of paraffin embedded Human Kidney. Steamed antigen retrieval with citrate buffer pH 6, HRP-staining.

179,145 Da

LDL receptor related protein 5

low-density lipoprotein receptor-related protein 5

Low-density lipoprotein receptor-related protein 5

LR3; LRP7; LRP-5??[Similar Products]

LRP5_HUMAN

This gene encodes a transmembrane low-density lipoprotein receptor that binds and internalizes ligands in the process of receptor-mediated endocytosis. This protein also acts as a co-receptor with Frizzled protein family members for transducing signals by Wnt proteins and was originally cloned on the basis of its association with type 1 diabetes mellitus in humans. This protein plays a key role in skeletal homeostasis and many bone density related diseases are caused by mutations in this gene. Mutations in this gene also cause familial exudative vitreoretinopathy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, May 2014]

LRP5: Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers beta-catenin signaling through inducing aggregation of receptor- ligand complexes into ribosome-sized signalsomes. Cell-surface coreceptor of Wnt/beta-catenin signaling, which plays a pivotal role in bone formation. The Wnt-induced Fzd/LRP6 coreceptor complex recruits DVL1 polymers to the plasma membrane which, in turn, recruits the AXIN1/GSK3B-complex to the cell surface promoting the formation of signalsomes and inhibiting AXIN1/GSK3- mediated phosphorylation and destruction of beta-catenin. Appears be required for postnatal control of vascular regression in the eye. Required for posterior patterning of the epiblast during gastrulation. Homodimer; disulfide-linked. Forms phosphorylated oligomer aggregates on Wnt-signaling. Component of a Wnt-signaling complex that contains a WNT protein, a FZD protein and LRP5 or LRP6. Interacts with FZD8; the interaction is formed on WNT-binding and signaling. Interacts (via the phosphorylated PPPSP motif domains) with AXIN1; the interaction prevents inhibition of beta-catenin phosphorylation and signaling and is enhanced in the presence of GSK3B and WNT1 or WNT3A. Interacts (via beta-propeller regions 3 and 4) with DKK1; the interaction, enhanced by MESD and/or KREMEN, inhibits beta-catenin signaling by preventing GSK3-mediated phosphorylation of the PPPSP motifs and subsequent, AXIN1 binding. Interacts with MESD; the interaction prevents the formation of LRP5 aggregates, targets LRP5 to the plasma membrane and, when complexed with KREMEN2, increases DKK1 binding. Interacts with CSNK1E. Interacts with SOST; the interaction antagonizes canonical Wnt signaling. Interacts with APCDD1. Widely expressed, with the highest level of expression in the liver and in aorta. Belongs to the LDLR family.

Protein type: Membrane protein, integral; Receptor, misc.

Chromosomal Location of Human Ortholog: 11q13.4

Cellular Component: endoplasmic reticulum; integral to membrane; mitochondrion; plasma membrane; receptor complex

Molecular Function: protein binding; toxin transporter activity; Wnt receptor activity; Wnt-protein binding

Biological Process: anatomical structure regression; anterior/posterior pattern formation; bone marrow development; bone remodeling; cell migration involved in gastrulation; cholesterol homeostasis; cholesterol metabolic process; embryonic digit morphogenesis; endocytosis; gastrulation with mouth forming second; glucose catabolic process; negative regulation of osteoblast differentiation; osteoblast development; positive regulation of cell proliferation; positive regulation of fat cell differentiation; positive regulation of mesenchymal cell proliferation; positive regulation of mitosis; positive regulation of osteoblast proliferation; positive regulation of transcription factor activity; positive regulation of transcription from RNA polymerase II promoter; positive regulation of transcription, DNA-dependent; regulation of apoptosis; regulation of blood pressure; regulation of bone remodeling; retina morphogenesis in camera-type eye; somatic stem cell maintenance; Wnt receptor signaling pathway; Wnt receptor signaling pathway through beta-catenin

Disease: Bone Mineral Density Quantitative Trait Locus 1; Endosteal Hyperostosis, Autosomal Dominant; Exudative Vitreoretinopathy 1; Exudative Vitreoretinopathy 4; Osteopetrosis, Autosomal Dominant 1; Osteoporosis; Osteoporosis-pseudoglioma Syndrome; Van Buchem Disease, Type 2

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.